Polyfunctional CD4+ T cell responses in HIV-1-infected viral controllers compared with those in healthy recipients of an adjuvanted polyprotein HIV-1 vaccine  by Van Braeckel, Eva et al.
P
w
E
C
a
b
c
A
R
R
A
A
K
H
H
V
C
1
w
e
F
h
I
w
T
i
D
f
0
hVaccine 31 (2013) 3739– 3746
Contents lists available at SciVerse ScienceDirect
Vaccine
jou rn al hom ep age: www.elsev ier .com/ locat e/vacc ine
olyfunctional  CD4+ T  cell  responses  in  HIV-1-infected  viral  controllers  compared
ith  those  in  healthy  recipients  of  an  adjuvanted  polyprotein  HIV-1  vaccine
va  Van  Braeckela,  Isabelle  Desomberea, Frédéric  Clementa, Linos  Vandekerckhoveb,
hris  Verhofstedec, Dirk  Vogelaersb, Geert  Leroux-Roelsa,∗
Center for Vaccinology, Ghent University and Hospital, Ghent, Belgium
AIDS Reference Center, Ghent University and Hospital, Ghent, Belgium
AIDS Reference Laboratory, Ghent University and Hospital, Ghent, Belgium
a  r  t  i  c  l e  i  n  f  o
rticle history:
eceived 26 December 2012
eceived in revised form 11 April 2013
ccepted 8 May 2013
vailable online 21 May 2013
eywords:
IV-1
IV-1 vaccine
iral controllers
D4+ T cell response
a  b  s  t  r  a  c  t
A  recombinant  fusion  protein  (F4)  consisting  of  HIV-1  p17,  p24,  reverse  transcriptase  (RT)  and  Nef,  adju-
vanted  with  AS01,  induced  strong  and broad  CD4+ T cell  responses  in healthy  volunteers.  Here  we  compare
these  vaccine-induced  CD4+ T cell responses  with  the  ones  induced  by  natural  infection  in  patients  with
varying  disease  courses.
Thirty-eight  HIV-infected,  antiretroviral  treatment-naïve  subjects  were  classiﬁed  into  four  categories:
8  long-term  non-progressors  (infection  ≥7  years;  CD4+ T cells  ≥500/L),  10 recently  infected  individuals
(infection  ≤2 years;  CD4+ T cells  ≥500/L),  10  typical  early  progressors  (CD4+ T cells  ≤350/L),  and  10
viral  controllers  (plasma  HIV-1  RNA  <1000  copies/mL).  Peripheral  blood  mononuclear  cells  were  stimu-
lated  in  vitro  with  p17,  p24,  RT  and  Nef  peptide  pools  and  analyzed  by  ﬂow  cytometry  for  expression  of
IL-2, IFN-,  TNF-  and  CD40L.  CD4+ T cell responses  were  compared  to  those  measured  with  the  same
method  in 50  HIV-uninfected  subjects  immunized  with  the  F4/AS01  candidate  vaccine  (NCT00434512).
After  in  vitro stimulation  with  p17,  p24  and  RT  antigen  viral  controllers  had  signiﬁcantly  more  CD4+ T
cells  co-expressing  IL-2, IFN-  and  TNF-  than  other  HIV  patient  categories.  The  magnitude  and  quality  of
these  responses  in  viral  controllers  were  comparable  to those  observed  in F4/AS01  vaccine  recipients.  In
contrast  with  viral  controllers,  triple  cytokine  producing  CD4+ T cells  in  vaccinees  also  expressed  CD40L.
Subjects  who  spontaneously  control  an  HIV  infection  display  polyfunctional  CD4+ T  cell responses  to
p17,  p24,  RT and  Nef, with  similar  magnitude  and  qualities  as  those  induced  in healthy  volunteers  by  an
e  vacc
e Auadjuvanted  HIV  candidat
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. IntroductionWith an estimated 33.3 million people currently infected
ith human immunodeﬁciency virus (HIV) worldwide, the global
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HIV/AIDS pandemic has completed its third decade [1]. A fully
efﬁcacious vaccine providing durable protection against HIV type
1 (HIV-1) would deﬁnitely have the biggest impact on HIV inci-
dence [2]. However, a disease-modifying HIV vaccine, generating
an immune response that helps to control virus load, prevents
progression of disease in HIV-infected patients, and reduces viral
transmission, remains a valuable alternative [3].
The lack of natural protective immunity against HIV is the main
obstacle in deﬁning immune correlates of protection [4,5] and sug-
gests that an effective vaccine will need to generate an immune
response that is superior to the natural immune response [6]. The
quality of the CD4+ (or CD8+) T cell cytokine response, estimated by
enumerating polyfunctional T cells co-producing gamma interferon
(IFN-), interleukin-2 (IL-2) and tumor necrosis factor alpha (TNF-
), is considered a possible correlate of vaccine-induced protection
[7].
Open access under CC BY-NC-ND license. As the main target of HIV [8], CD4+ T cells are pivotal in HIV
pathogenesis and wide controversy exists concerning their role
in control versus promotion of HIV replication [9]. Nevertheless,
the role of CD4+ T cells in induction and maintenance of efﬁcient
C-ND license. 
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emory CD8+ T cell and B cell responses is well established and
onsidered of pivotal importance [10–12]. Moreover, evidence
upporting direct antiviral effects of HIV-speciﬁc CD4+ T cells is
rowing [13–15]. It is therefore generally believed that an effective
IV vaccine will need to elicit a robust CD4+ T cell response [9,16].
his is illustrated by the modest success of the Thai vaccine trial,
n which decreased HIV acquisition was observed with a CD4+ T
ell-inducing vaccine [17].
Studying subpopulations of untreated HIV-infected patients
ith slow disease progression, as deﬁned by immunologic or
irologic parameters, allows us to obtain more insights into the
rotective mechanisms [18,19]. Long-term non-progressors (LTNP)
emain asymptomatic for many years and maintain high CD4 cell
ounts without antiretroviral therapy (ART), whereas viral con-
rollers (VC) spontaneously suppress viral replication [19]. VC and
TNP share some characteristics but have distinct clinical pheno-
ypes, while in the literature varying deﬁnitions are encountered
3,19–21]. Some VC experience clinical progression despite viral
ontrol, and some LTNP maintain high levels of viremia [3].
HIV-speciﬁc CD4+ T cell-mediated immune responses have been
hown to correlate with LTNP and/or VC phenotypes [22–29]. Both
on-progression and control of HIV replication are believed to be
ssociated with high frequencies of HIV-1 Gag-speciﬁc CD4+ T cells
ecreting both IFN- and IL-2 [23,26]. Subsequent studies have
inked suppression of viremia to maintenance of highly functional
D4+ T cells co-producing IFN-, IL-2 and TNF- in response to Gag
nd preserved proliferative responses to p24 [28,29]. In addition,
D4+ T cells from LTNP exhibited strong proliferative responses and
FN- secretion after stimulation with Nef-peptides [27].
Assuming that these CD4+ T cell responses directly contribute
o the more benign course of the infection in VC, the challenge is
o design a vaccine that induces these beneﬁcial cellular immune
esponses [16]. The present study has been performed to com-
are CD4+ T cell responses to a wide range of HIV-1 antigens,
nduced by natural HIV-1 infection in patients with different dis-
ase courses, with the responses induced in healthy volunteers by
accination with the same set of antigens. The latter responses were
nduced in vivo and analyzed in vitro during a recent clinical trial in
hich HIV-uninfected volunteers were immunized with a recom-
inant fusion protein (F4) comprised of HIV-1 p17 and p24 Gag,
everse transcriptase (RT) and Nef, adjuvanted with AS01 [30]. The
mmune markers measured in vitro were the simultaneous produc-
ion of IFN-, IL-2 and/or TNF-, and the expression of CD40-ligand
CD40L) as a T cell activation marker.
. Materials and methods
.1. Study design and participants
This was a single center cross-sectional observational study. The
IV-infected patients were recruited at the AIDS Reference Center
ARC), Ghent University Hospital (Ghent, Belgium). The data from
he vaccinated uninfected (VU) volunteers were obtained from a
linical trial conducted at the Center for Vaccinology, Ghent Uni-
ersity and Hospital, registered with the ClinicalTrials.gov registry
NCT00434512) [30]. The study was approved by the local indepen-
ent ethics committee (Ghent University Hospital) and conducted
n accordance with the Declaration of Helsinki and Good Clinical
ractice guidelines. Written informed consent was  obtained from
ll subjects prior to study entry.
Thirty-eight HIV-1-infected male and female adults between 18
nd 69 years of age were recruited and divided into four study
roups. Standard eligibility criteria were used for enrolment into
he study. Exclusion criteria included receipt of live attenuated vac-
ines within 30 days, other vaccine or antigen injections within
4 days, or blood products or immunoglobulins 120 days priore 31 (2013) 3739– 3746
to enrolment, as well as chronic administration of immunosup-
pressants or immune-modifying drugs within 6 months prior to
enrolment. The group-speciﬁc inclusion criteria were pre-deﬁned
as follows: LTNP were diagnosed with HIV-1 infection since ≥7
years, and had repeated and most recent CD4+ T cell counts
≥500/L in the absence of ART or AIDS-related symptoms. Recently
infected (RI) individuals had a documented HIV-1 infection since <2
years, and repeated and most recent CD4+ T cell counts ≥500/L,
in the absence of ART or AIDS-related symptoms. Typical progres-
sors had repeated and most recent CD4+ T cell counts ≤350/L in
the absence of ART and were named typical early progressors (TEP)
since the median time since diagnosis was  only 1.8 years (Table 1). A
VC status was  deﬁned as repeated and most recent HIV plasma RNA
levels (viral load) <1000 copies/mL in the absence of ART or AIDS-
related symptoms. Subjects were selected from the ARC database
of patients in regular follow up and included consecutively in order
of appearance at the HIV clinic (n = 8 for the LTNP group, n = 10 for
each of the RI, TEP and VC groups). All patients were ART-naïve,
except for subject F04 who was treated during a pregnancy 3 years
before inclusion. Clinical data were recorded retrospectively.
The vaccinated uninfected (VU) subjects were healthy male and
female adults aged 18–41 years at low risk of HIV infection who  had
received two  doses of the F4/AS01 study vaccine (GlaxoSmithKline
(GSK) Biologicals, Rixensart, Belgium) with 1 month interval [30].
This vaccine consisted of 10 g per dose of F4 recombinant protein
adjuvanted with AS01. F4 is a recombinant fusion protein com-
prised of four HIV-1 subtype B antigens, namely p24, RT, Nef and
p17. AS01 is a liposome-based adjuvant system containing 50 g
MPL  and 50 g QS21. The immunogenicity data of month 2 (day
60) were used for this comparative study [30].
2.2. T cell responses
T cell responses were evaluated by intracellular cytokine
staining (ICS) following in vitro stimulation with pools of 15-
mer  peptides overlapping by 11 amino acids (Eurogentec, Liège,
Belgium) covering the sequences of HIV-1 clade B p17, p24, RT and
Nef to assess the expression of CD40L and/or the production of IL-2,
IFN- and/or TNF-. The ICS was  performed on thawed periph-
eral blood mononuclear cells (PBMC) that had been isolated from
venous blood by standard Ficoll-Isopaque density gradient cen-
trifugation and cryopreserved in liquid nitrogen. This ICS procedure
has been described elsewhere [30]. PBMC from the HIV-infected
patient groups were also tested after stimulation with gp120 and
Tat peptide pools (Eurogentec), as described in a previous vaccine
study report [31]. Analyses were performed with an LSR II ﬂow
cytometer (BD Biosciences, Erembodegem, Belgium) and FACS-
Diva software (BD Biosciences). The mean number of CD4+ T cells
measured for each condition was  52,638 (minimum 10,942, maxi-
mum 121,295). The ICS results were expressed as the percentage of
the total CD4+ and CD8bright T cells expressing the immune markers
IL-2, IFN-, TNF- and/or CD40L in response to stimulation with
p17, p24, RT, Nef, Tat or gp120 antigens minus the frequency of
CD4+ and CD8bright T cells expressing these cytokines upon in vitro
culture in medium only.
2.3. Statistical analysis
The frequency of CD4+ and CD8+ T cells expressing each marker
and combinations of markers following in vitro stimulation by
each individual antigen was determined. Spearman correlations
with viral load were calculated for all HIV-1-infected patients,
irrespective of the patient group. To minimize bias induced by mul-
tiple comparisons, signiﬁcant differences between HIV-1-infected
patient groups were ﬁrst identiﬁed using a Kruskal–Wallis test
as a screening method. Subsequently, two-by-two Mann–Whitney
E. Van Braeckel et al. / Vaccine 31 (2013) 3739– 3746 3741
Table 1
Patient characteristics.
ID Sex Age Origin Timea (years) Transmissionb CCR5 genotype HIV-1 subtypec CD4 countd (cells/L) Viral loadd (copies/mL)
Long-term non-progressors
LTNP01 M 44 Hispanic 19.3 MSM wt/wt B 570 1778
LTNP02 F 45 Caucasian 18.8 HE wt/wt F1 434 2344
LTNP03 M 34 Caucasian 22.9 BT wt/32 B 477 7586
LTNP04 F 46 Caucasian 8.9 HE wt/wt 02 AG 696 468
LTNP05 F 56 Caucasian 12.1 HE wt/wt G 486 2042
LTNP06 F 69 Caucasian 9.8 HE wt/32 02 AG 1080 <50
LTNP07 F 33 African 7.9 HE wt/wt 02 AG 534 210
LTNP08 F 42 Caucasian 17.0 IVD wt/wt ? 885 <50
Median [IQR] 45 [13] 14.6 [9.7] 552 [309] 1123 [2087]
Recently infected individuals
RI01 M 35 Hispanic 1.2 MSM wt/wt B 496 64,565
RI02  M 24 Caucasian 0.7 MSM wt/wt B 593 10,2239
RI03  M 62 Caucasian 1.6 MSM wt/wt B 918 23,442
RI04  M 32 Caucasian 1.4 MSM wt/wt B 651 3090
RI05  M 36 Caucasian 1.3 MSM wt/wt B 563 643
RI06  M 36 Caucasian 1.9 MSM wt/wt B 1360 1122
RI07  F 31 African 1.9 ? wt/wt A1 451 35,481
RI08  M 27 Caucasian 2.0 MSM wt/wt B 568 57,544
RI09  M 48 Caucasian 0.9 MSM wt/wt B 756 43,652
RI10  M 53 Caucasian 1.8 MSM wt/32 B 559 20,417
Median [IQR] 35 [17] 1.5 [0.7] 581 [197] 29,462 [54,454]
Typical  early progressors
TEP01 M 32 Caucasian 2.5 MSM wt/wt B 341 114,815
TEP02 M 30 Caucasian 2.1 HE wt/wt B 334 44,668
TEP03  M 42 Caucasian 0.5 MSM wt/wt B 334 151,356
TEP04 M 48 Caucasian 2.5 MSM wt/wt B 199 18,197
TEP05  M 36 Caucasian 2.0 MSM wt/32 B 242 53,703
TEP06  F 28 African 1.0 HE wt/wt C 239 380
TEP07  M 31 Asian 1.0 MSM wt/wt B 260 66,069
TEP08  M 41 Caucasian 0.5 MSM wt/wt B 230 25,400
TEP09 M 40 Caucasian 2.1 HE wt/wt 01 AE 248 5888
TEP10  M 28 Caucasian 1.7 MSM wt/32 B 162 24,547
Median [IQR] 34 [11] 1.8 [1.1] 245 [104] 35,034 [47,872]
Viral  controllers
VC01 M 27 Asian 3.0 MSM wt/wt 01 AE 864 642
VC02  F 40 African 11.8 HE wt/wt C 442 <50
VC03  F 50 African 20.7 HE wt/wt A1 321 <50
VC04  F 33 African 3.7 HE wt/wt 02 AG 518 56
VC05  M 43 African 3.8 HE wt/wt 01 AE 613 541
VC06  M 30 Caucasian 3.9 MSM wt/wt B 503 163
VC07  F 55 Caucasian 1.3 HE wt/32 ? 1210 <50
VC08  M 32 African 4.3 HE wt/wt 02 AG 904 <50
VC09  F 44 Caucasian 5.7 HE wt/wt ? 1010 <50
VC10  M 43 Caucasian 8.1 MSM wt/wt C 413 <50
Median [IQR] 41 [12] 4.1 [4.4] 566 [462] <50 [113]
a Time since diagnosis of HIV-1 infection at time of blood sampling.
b HIV-1 transmission route. MSM,  men-who-have-sex-with-men; HE, heterosexual; BT, blood transfusion; IVD, intravenous drug use; and ?, unknown.
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cc HIV-1 subtype. ?, unknown.
d Most recent CD4+ T cell count and HIV-1 viral load at time of blood sampling (ra
onths, respectively).
omparisons between groups were carried out on conditions iden-
iﬁed by the Kruskal–Wallis test. All statistics were performed using
ASW Statistics 18 (SPSS Inc., Chicago, IL).
. Results
.1. Clinical characteristics
A total of 38 HIV-infected subjects were studied, including 8
TNP, and 10 subjects in each of the three other groups (RI, TEP,
nd VC). Their demographic, clinical and virological characteristics
re listed in Table 1. Patient LTNP08 was co-infected with hepatitis
 and hepatitis C virus (HCV); patients RI08 and VC02 were both
o-infected with HCV. Although patients were randomly selected,–8.3 months, median time between CD4 count or viral load and inclusion 0.2 or 0.4
there was  a predominance of clade B infections in the RI and TEP
groups, whereas the LTNP and VC patients were infected with a
more heterogeneous mix  of HIV-1 subtypes. Since the duration of
infection in the RI and TEP was shorter than that in LTNP and VC,
this difference probably results from speciﬁc characteristics of the
local epidemic with HIV-1 subtype B infected Caucasian men-who-
have-sex-with-men (MSM)  accounting for the majority of recent
local HIV transmissions while the majority of non-B infections are
found in other ethnic groups [32]. Not surprisingly, there was some
overlap between groups, with four LTNP also fulﬁlling the criteria
for inclusion in the VC group. Statistical signiﬁcance of the data
described below was not affected if those four patients were added
to the VC group. The VC group contained six so-called elite con-
trollers with undetectable viral load.
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Fig. 1. Overview of polyfunctional HIV-speciﬁc CD4+ T cell responses. (A) Signiﬁcant differences between the four HIV-1-infected patient groups (LTNP, RI, TEP, VC) were ﬁrst
identiﬁed using a Kruskal–Wallis test as a screening method. The rows indicate various combinations of markers expressed by CD4+ T cells. The columns indicate the different
H ray in
c ed coh
w
3
l
A
e
(
aIV-1  antigens used for stimulation. The signiﬁcance levels are indicated by the g
onditions identiﬁed by the Kruskal–Wallis test, including the vaccinated uninfect
hen  reading the charts from the left to the right.
.2. CD4+ T cell responses
Inverse correlations were observed between HIV plasma RNA
evels and different expressions of CD4+ T cell polyfunctionality. lower viral load correlated with co-expression of four mark-
rs (CD40L, IL-2, IFN- and TNF-) after stimulation with p24
p < 0.001), with triple cytokine production (IL-2, IFN- and TNF-)
fter stimulation with p17, p24 (both p < 0.001) and RT (p = 0.005),tensities. (B) Two-by-two Mann–Whitney comparisons were performed on those
ort (VU). The symbols “>” and “<” indicate greater and smaller than, respectively,
and with co-production of IL-2 and TNF- after stimulation with
p24 (p = 0.003) and RT (p = 0.005). No correlations were found with
CD4 responses to gp120, Nef and Tat.
The CD4+ T cell responses against p17, p24, RT and Nef,
induced by the F4co/AS01 vaccine candidate in healthy volunteers,
were generally higher than those observed in infected patients.
We considered the responses that were different among HIV-1-
infected patient groups as the most relevant ones, identiﬁed by a
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ackground subtracted.
ruskal–Wallis test (Fig. 1A) and subsequently further differenti-
ted between the four patient groups and the vaccinees (Fig. 1B).
imultaneous expression of 4 markers was higher in VU than in
ost HIV-1-infected patients (Figs. 1 and 2). Among HIV-1-infected
atients, VC had the highest frequencies of polyfunctional CD4+ T
ells co-expressing 4 markers or co-producing 3 cytokines when
timulated with p17, p24 and RT antigen (Figs. 1 and 3). There
as no statistically signiﬁcant difference between elite and viremic
ontrollers. After stimulation with Nef, VC had more CD4+ T cells
xpressing both IL-2 and TNF- than other patient groups. For
ll antigens, the differences between VC and other HIV-1-infected
atients fade out when combinations of only two markers or only
ne marker are considered. After stimulation with Tat and gp120,
o signiﬁcant differences between groups were observed (Fig. 1A).
ig. 4 summarizes all antigen-stimulated conditions of CD4+ T cells
xpressing 1, 2 or 3 cytokines among IFN-, IL-2 and TNF-..3. CD8+ T cell responses
The CD8bright T cell responses observed in the HIV-infected
atient groups are available online as supplementary data. The
ig. 3. CD4+ T cells co-expressing IL-2, IFN- and TNF-. Horizontal lines represent group
han  TEP (p = 0.001), RI (p = 0.003) and LTNP (p = 0.007) after p17 stimulation, than TEP 
p  = 0.011) and RI (0.034) after RT stimulation. **VU signiﬁcantly higher than TEP (p = 0.0
fter  p24 stimulation, and than RI, LTNP and TEP (all p ≤ 0.001) after RT stimulation.sion after stimulation with p17, p24, RT or Nef. Results (group means, SEM) are
TNF-), with or without simultaneous CD40L expression. All responses shown are
F4/AS01 vaccine candidate induced no detectable CD8+ T cell
responses.
4. Discussion
This is the ﬁrst report of a head-to-head comparison of CD4+
T cell responses induced by HIV infection in individuals with dif-
ferent patterns of disease progression and CD4+ T cell responses
induced by an HIV-1 vaccine candidate in healthy volunteers. The
data show that vaccination of healthy HIV-uninfected volunteers
with an adjuvanted polyprotein vaccine induced polyfunctional
CD4+ T cell responses to p17, p24, RT and Nef of the same mag-
nitude and quality as those observed in HIV-infected patients who
spontaneously control the virus.
HIV-infected VC had signiﬁcantly more CD4+ T cells co-
expressing IL-2, IFN- and TNF- after stimulation with p17, p24
and RT antigen than other HIV patient categories. Differences
between study groups decreased with lowering polyfunctionality.
With exception of the combination of IL-2 and TNF-, the produc-
tion of only one or two cytokines by antigen-speciﬁc CD4+ T cells
was comparable for all HIV patient groups, irrespective of the viral
load. Our results are in line with previous studies, wherein Gag was
 medians. All responses shown are background subtracted. *VC signiﬁcantly higher
(p = 0.005), RI (p = 0.019) and VU (p = 0.026) after p24 stimulation, and than LTNP
01), RI (p = 0.002) and LTNP (p = 0.020) after p17 stimulation, than TEP (p = 0.033)
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roducing CD4+ T cells expressing 1, 2 or 3 cytokines (IL-2, IFN- or TNF-). Freque
hart.  The sizes of the pies reﬂect these percentages. The F4/AS01 vaccine candidat
ost often used as a stimulating antigen. Both non-progression
nd durable control of HIV replication have been associated with
igh levels of Gag-speciﬁc IL-2+ IFN-+ CD4+ T cells in studies
herein TNF- expression was not measured [23,26]. Strong p24-
peciﬁc CD4+ T cell responses have also been linked to efﬁcient viral
ontrol in primary HIV-1 infection [25] and a stable p24-speciﬁc
roliferative response to control of viremia and retention of non-
rogressor status [29]. Kannanganat et al. demonstrated that CD4+
 cells producing three cytokines are functionally superior to those
roducing single cytokines and that control of HIV-1 is associated
ith the maintenance of highly functional Gag-speciﬁc CD4+ T cells
o-producing IL-2, IFN- and TNF- [28,33]. A recent analysis of
D4+ T cell responses to the entire HIV proteome in 93 subjects
t different stages of HIV infection, indicated Gag as the target of
FN-+ CD4+ T cells most robustly associated with lower levels of
iremia [34]. Responses to three distinct Gag epitopes were linked
o spontaneous HIV control.
We also found that TEP had lower frequencies of HIV-speciﬁc
D8+ T cells producing IL-2 alone or in combination with TNF-
, when compared to VC and also RI. This is consistent with theroup. Results (group means) were expressed as the percentage of the total cytokine-
 (%) of total CD4+ T cells producing at least 1 cytokine are indicated above each pie
ained no Tat or gp120 antigens. Responses shown are background subtracted.
ﬁndings of Betts et al., who demonstrated that CD8+ T cells of
non-progressors retain the capacity to produce TNF- and IL-2
in conjunction with other functions, such as degranulation and
chemokine production [35]. Another study, using IFN- enzyme-
linked immunospot assays, indicated that Gag-speciﬁc responses
were associated with lowering viremia, while Env-speciﬁc and
Accessory/Regulatory protein-speciﬁc responses were associated
with higher viremia [36]. In our patients, we also observed that
TEP had more gp120- and Nef-speciﬁc CD8bright T cells expressing
IFN- (in combination with CD40-L) than VC.
The CD4+ T cell responses of the LTNP in our study resembled
better those of TEP and RI than of VC. This may  be due to the fact
that most LTNP in our cohort had detectable plasma HIV RNA levels
and had reached a certain phase of disease progression at the time
of inclusion. The two LTNP with undetectable viral load, subjects
LTNP06 and 08, showed the highest functional CD4 responses of
the LTNP group, the magnitude of which was comparable to the
group medians of the VC. Our explanation of this unexpected ﬁnd-
ing is supported by the results of a longitudinal study which showed
that detectable viremia at study entry was  predictive of loss of LTNP
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tatus and/or disease progression and differentiated slow progres-
ors from elite LTNP who retained potent virological control [29].
ogether these data suggest that the viral load is a better predictor
f functional HIV-speciﬁc immunity than the CD4 count.
The magnitude and quality of the CD4+ T cell responses in VC
ere comparable to those observed in F4/AS01 vaccine recipients.
his was most pronounced after stimulation with RT, when co-
xpression of IL-2, IFN- and TNF- was similar to VC but more
requent than in TEP, RI and LTNP. No comparisons were pos-
ible at the CD8 level because the F4/AS01 vaccine induced no
etectable CD8 responses. Our results demonstrate that in healthy
ubjects an adjuvanted polyprotein HIV vaccine can induce CD4+
 cell responses that share several characteristics with the HIV-
peciﬁc immune response detected in the peripheral blood of
IV-infected patients able to spontaneously control HIV viremia.
oth prospective studies and vaccination trials in HIV-infected
atients are needed to provide further evidence on the hypothesis
hat these immune responses are cause rather than consequence
f viral suppression. The results of these vaccine studies will deter-
ine which subgroups within all prevalent HIV-infections may
eneﬁt from such immunotherapy. A CD4+ T cell-inducing vac-
ine targeting the appropriate set of HIV antigens might be able to
nduce a non-progression status in vaccinated, chronically infected
atients.
The CD40L protein delivers activating signals to B-cells and
ntigen presenting cells when expressed by activated T cells.
dministration of the adjuvanted HIV vaccine to healthy volun-
eers induced CD40L expression on practically all polyfunctional
IV-speciﬁc CD4+ T cells co-producing 3 cytokines. Interestingly,
n HIV-infected controllers a similar pool of triple cytokine pro-
ucing CD4+ T cells was found but the majority of these cells
id not express CD40L (Fig. 2). This ﬁnding is consistent with
he HIV-induced impairment of CD40L expression on CD4+ T cells
escribed by other groups, which is thought to contribute to
ntigen-presenting cell dysfunction in HIV infection [37,38].
A possible weakness of this study is the heterogeneity in viral
ubtypes seen in the LTNP and VC groups, whereas in the other
roups patients were mainly infected with viruses of clade B. An
nﬂuence of varying viral ﬁtness can therefore not be excluded.
owever, although all peptides used in the ICS assays were derived
rom clade B viruses, we observed the most vigorous responses in
he VC group in which only one clade B infection was present. This
uggests a high degree of cross-reactivity at the T cell level between
he different clades, similar to what has been observed before in the
4/AS01 vaccinees with clades A and C peptides [30]. Since we  have
ot examined the patients’ HLA types we cannot estimate the pos-
ible effects of protective class I alleles, such as B*5701 and B*27
39]. Genotyping for the CCR5 32-mutation that has been asso-
iated with slower disease progression revealed no homozygous
nd a balanced representation of heterozygous patients in all study
roups.
This comparison of HIV-speciﬁc CD4+ T cell responses induced
y natural infection on the one hand and by a candidate HIV vaccine
n the other hand, provides for the ﬁrst time direct evidence that
dministration of an adjuvanted polyprotein vaccine can induce
n immune response with qualities similar to that observed in
IV-infected patients who spontaneously control the virus. If a
ausal relation between this observed immune response and viral
ontrol can be proven further, administration of an adjuvanted
ulti-antigenic vaccine might produce an immune status that will
irect the disease course toward the VC status in case of subse-
uent HIV infection. Controlling the viral load is not only beneﬁcial
or the individual patient but has also impact on the spread of the
irus in the community. Our observations need to be corroborated
ut warrant further exploration of the F4/AS01 vaccine candidate
n HIV-1-infected patients as an immunotherapeutic approach.
[
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